Invention Grant
- Patent Title: LXR inverse agonists for treatment of cancer
-
Application No.: US16311941Application Date: 2017-06-23
-
Publication No.: US11746097B2Publication Date: 2023-09-05
- Inventor: Thomas Burris , John K. Walker , Colin Flaveny , Arindam Chatterjee
- Applicant: Saint Louis University
- Applicant Address: US MO St. Louis
- Assignee: Saint Louis University
- Current Assignee: Saint Louis University
- Current Assignee Address: US MO Saint Louis
- Agency: Parker Highlander PLLC
- International Application: PCT/US2017/039116 2017.06.23
- International Announcement: WO2017/223514A 2017.12.28
- Date entered country: 2018-12-20
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D217/26 ; C07D401/12 ; C07D217/06 ; C07D417/04 ; C07D409/04 ; C07D215/38 ; A61K9/00

Abstract:
In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.
Public/Granted literature
- US20200308135A1 LXR INVERSE AGONISTS FOR TREATMENT OF CANCER Public/Granted day:2020-10-01
Information query